The uniqueness associated to Cell and Gene Therapy is due to an extensive list of variables, such as high COGS, operational complexity, sophisticated HTA submissions, health systems readiness, patient choice, individualized QC and QA release, forecast capacity, initial high infrastructure investments and a flawless ordering system. The complexity level and the risks are high – applying the blueprint of a traditional pharmaceutical launch plan does not translate well in this environment. Although certain knowledge and skillsets from other pharmaceutical launches are transferrable, a new skills set is needed to create profitable commercialization plan. CAR-T Global is a firm that specializes in the commercialization of Cell and Gene Therapy Assets. Whether your company has assets in Phase 1 or has approved Cell and Gene Therapy products, we have the expertise to support your company aspirations. Our mission is to make your asset a reality.
CAR-T Global Consultant Inc. is a consulting firm dedicated to the commercialization of Cell and Gene Therapies. Through our two key specialized divisions, we support the commercialization of CGTs in established markets while also working to expand access to affordable CAR-T treatments in emerging countries. By combining proven expertise with innovative solutions, we help bring lifesaving therapies to patients globally.
We have a strong network of talented individuals with specific expertise in CAR T. Depending on the scope of the project, we will bring in the best experts to support your goals. All projects will be handcrafted and fully executed by our lead executive consultant.
Our mission has always been to make cell and gene therapies a reality. With this team, we were inspired to strengthen efforts in established markets and expand beyond them. We believe every patient should have access to life-saving medicine, no matter where they live.
Founded CAR-T Global in 2021, a consulting firm dedicated to supporting the commercialization of cell and gene therapies across both established and emerging markets. Former Head of CAR-T Marketing and National Lead of CAR-T Operations at Celgene/BMS (Canada), with additional leadership roles in National Patient Access and Early Pipeline Commercialization, supporting the national launch and scale-up of CAR-T therapies.
Experienced, independent thought leader in the Value & Access and Health Economics fields, with broad and deep global exposure and proven leadership capabilities in cell therapy, oncology, neuroscience and vaccines. Jose Manuel is highly experienced with a a diverse portfolio of business development strategy & execution.
The science is not the issue, the science has delivered. What is not working is the bio pharma business model in cell and gene therapy is failing patients and its even failing investors. We want to change that.
Our team's diversity aids in covering considerations relevant to cell and gene therapy expansion from every angle. Diversity ensures that this collaboration truly drives global impact.
Hematologist-oncologist and former Executive Director and Global Head of Tecartus Clinical Development at Kite Pharma. He is a seasoned executive with extensive experience in developing and commercializing transformative therapies. He has led multiple clinical programs and regulatory strategies across multiple platforms to being innovative treatments to patients worldwide.
Former commercial operations lead global expansion at Kite and Apheresis/supply chain lead at Novartis Passionate about the transformative potential of cell therapy and sees it as a new frontier in medicine that offers hope and meaningful outcomes for patients. With an entrepreneurial and solution-oriented mindset, Andreas thrives in dynamic environments, embracing complexity as an opportunity to innovate, collaborate, and turn bold ideas into real-world solutions.
Working in a small team where everyone shares the same passion for increasing accessibility is fantastic, because we have both the control and decisionmaking to design efficient processes that truly create change.
While progress has been made in expanding access to less complex treatments, there is still much to be done to ensure that patients in underserved regions can receive the therapies they urgently need.
Former Head Market Access/Policy at Novartis & AbbVie and consultant leader in access and partnerships Brings senior-level experience in the life sciences and healthcare sector, having led strategic change and market access initiatives across Asia Pacific and other emerging markets. Jeff’s background spans executive industry roles and consulting leadership, with expertise in corporate strategy, market access, digital health, business development, and commercialization advisory.
A business development and regulatory affairs executive with over 25 years of experience in the pharmaceutical industry. Arturo has a proven track record of securing regulatory approvals across Europe, Latin America, and MEA, and is a registered pharmacist in the UK, Spain, Colombia, and Sweden.
My motivation is to deliver hope and life choices to patients who currently have no options.
Whether your company has assets in Phase 1 or has approved Cell and Gene Therapy products, we have the expertise to support your company aspirations. We understand that if you are a small Biotech, you’ll have specific needs to strengthen and secure your commercialization pathways. We also understand that if you are part of a bigger pharmaceutical company with current marketed assets and others in the pipeline, you have different priority needs such as product differentiation, best-in-class execution, and KOL engagement.
As a new global boutique Cell and Gene Therapy consulting company, we successfully support projects in cutting edge scientific fields such as CAR T, TCR, AAV Gene Therapy, ADCs and CAR T Manufacturing Programs. Projects have included:
- Go-to-Market strategic planning
- Resource allocations - FTE strategic role identification - Scalable field model - Timeline mapping - Centers/Hospital prioritization
- Market Assessment - Marketing Plan - Medical Plan - Hospital Readiness Plan - Market Access Plan including price potential - Resource, timeline and milestone identification - Evidence Generation Plan
- Identify Key Opinion Leaders - Customer segmentation
- Tiering of hospitals - Mapping of activated CAR T sites
- Access to Key Opinion Leaders - Ad Board development and moderation - Strategic Council with Key Opinion Leaders
- One on One discussions
- Interviews at International Conferences
- Primary Investigators who present pivotal data - Discussion Guide, Interview, Video creation
- In-depth Key Opinion Leader mapping/targeting
Conventionally there are only 2 options: out-license / sell your assets to a larger firm or build a full commercialization structure. The latter requires extensive resources and expertise that most Biotech companies are often lacking. Our hybrid model offers Biotech the option to keep your assets and outsource the commercialization services – either until an identified milestone is met, or for as long as you deemed required. You maintain control while maximizing the internal value of your assets. The logistical, technical, scientific and regulatory requirements of Cell & Gene therapies are very specific. We will find and train the staff with these qualifications in the targeted country or region. We will then support a flawless omnichannel execution. Our CGT Contract Commercialization Organization will provide best-in-class teams with the required expertise in areas including and not limited to: Medical Affairs, Sales, Site Onboarding, Market Access and Regulatory Affairs. The full-service Cell & Gene Therapy specific Contract Commercialization Organization (CGT CCO) offers a cost-efficient commercial option, bringing these important assets to patients without delay.
The Problem: Patients in LMICs have little to no access to CAR-T therapy due to extreme costs, leaving less than 1% of patients able to receive treatment. For most cancer patients in LMICs, CAR-T treatments are essentially nonexistent, despite the fact that these regions bear the majority of the global cancer burden.
We believe that every patient deserves access to life-saving medicine, regardless of where they live. With years of experience in established markets, we’re equipped to pursue bold ambitions.
Swaminathan Murugappan, MD, PhD,Executive Advisor, CAR-T Global
MONTREAL, QC – February 4, 2026 – CAR-T Global, a specialized Cell and Gene Therapy consulting company, announces the appointment of Swaminathan (Swami) Murugappan, MD, PhD, as Executive Advisor for R&D and Medical Affairs. Dr. Murugappan is an accomplished physician-scientist with over 15 years of experience driving drug development from preclinical research through global commercialization. His extensive experience, including Chief Medical Officer roles for cell therapy and immune-oncology companies along with his leadership level roles at Kite Pharma and Amgen will deepen CAR T Global’s technical capabilities and service offerings to cell and gene therapy organizations. “I am thrilled to have Dr. Murugappan join our team. Dr. Murugappan’sextensive experience in clinical development, global regulatory strategy, and medical affairsfor CGTs will strengthen our capabilities in delivering consulting and strategic advice. I also see an important opportunity to further complete our range of services as we support companies through our CGTcommercialization-in-a-boxmodel,” said Guillaume Köszegi, Founder of CAR-T Global.
“I am thrilled by this opportunity, which will leverage my experience to help create access to transformative CGTs for every patient who needs them, specifically including those in low- and middle-income countries who currently lack these options,” said Dr. Murugappan. “Traditional pharma and biotech models, as well as global delivery frameworks, will have to reconfigure to adapt to the advent of CGTs. The promise these therapies represent is enormous, and I am excited to be able to contribute toward a future where geography no longer dictates a patient's access to life-saving innovation.” In Dr. Murugappan's previous role at Kite, a Gilead company, he was the global product and development lead for Tecartus, providing clinical oversight for its US filing and regulatory approval. He previously served as a clinical leader at Amgen, where he contributed to the development and global launches of Vectibix and ImLygic. Throughout his career, Dr. Murugappan has managed clinical strategies for various biotech organizations and has a proven track record in designing Phase 1 through 3 trials for CAR-T, T-cell engagers, and oncolytic viruses. His expertise spans both hematologic and solid tumor indications, and he has worked across global and regional roles to bring innovative therapies to market. Dr. Murugappan holds a PhD in Physiology from Temple University School of Medicine and an MD from Madras Medical College. He completed his Fellowship in Hematology-Oncology at the University of Washington.
Jose Manuel Garnica, Partner CAR T Global Consultant Inc.
MONTREAL, QC – June 12, 2024 – CAR T Global Consultant Inc., a specialized Cell & Gene Therapy consulting company, announces the appointment of Jose Manuel Garnica, PhD MBA, as Partner specializing in commercial, strategic, and business development consulting, with a focus on access, pricing and health economics, for organizations devoted to cell and gene therapies (CGTs). Dr. Garnica’s extensive experience, most recently as Senior Director, Value and Access at Kite, a Gilead company - and previously as Global Value & Access Director for the oncology pipeline at Amgen, will deepen CAR T Global Consultant Inc.’s capabilities and service offerings to cell and gene therapy organizations. “I am thrilled to have Jose Manuel join our team. Jose Manuel's extensive industry network and specialized knowledge in pricing and health economics of CGTs will strengthen our capabilities when providing consulting and strategic advice. I also see an important opportunity to complete our range of services as we support companies via our CGT 'commercialization in a box' offering.” said Guillaume Köszegi, Founder of CAR T Global Consultant Inc.
“I am thrilled by this opportunity, which will leverage my experience to help achieve access to CGTs to every patient who needs it,” said Dr. Garnica. “Traditional pharma and biotech models, as well as healthcare systems, will have to reconfigure to adapt to the advent of CGTs. The promise CGTs represent is enormous and I am excited to be able to contribute for meaningful impact.” In Dr. Garnica's previous role at Kite, a Gilead company, he was responsible for the timely reimbursement of CAR-Ts in various countries around the globe. He previously was the Global Market Access lead for the Kite pipeline, providing access, pricing and economic evidence insights to development programs. Prior to this, Dr. Garnica spent over 15 years in value & access and health economics roles at Amgen, Roche, Pfizer and BMS, in areas including oncology, multiple sclerosis and vaccines. Dr Garnica has worked in global, regional and local roles across the world, including the US, Canada, Latin America, Europe and East Asia. He currently volunteers for the Global Gene Therapy Initiative under Caring Cross and teaches at the University of Southern California, in Los Angeles. Dr. Garnica holds a PhD in Physical Chemistry from Imperial College London and an MBA from London Business School, both in the United Kingdom.
Montreal, January 17, 2024 /PRNewswire/- CAR T Global Consultant Inc. - a specialized Cell & Gene Therapy consulting company announces their newest offering in the form of a Contract Cell & Gene Therapy Organization that will provide Biotech companies a comprehensive go-to-market commercialization service while retaining their intellectual property. Guillaume Köszegi, Founder and President of CAR T Global Consultant observes: “Commercialization options for Biotechs are limited. Conventionally there are only 2 options: out-license / sell their asset to a larger firm or build a commercialization structure on their own. The latter requires extensive resources and expertise that most Biotech companies are often lacking. We see an opportunity to support companies with a hybrid model that allows them to keep their assets and outsource the commercialization services – either until an identified milestone is met, or for as long as is deemed required. In this fast-paced environment, companies can re-invest in R&D rather than the build out of a commercial organization. They maintain control while maximizing the internal value of their assets”. Furthermore, Mr. Köszegi explains that: “The logistical, technical, scientific and regulatory requirements of Cell & Gene therapies are very specific. Finding and training staff with these qualifications in each specific country∕region can be difficult. Our CGT Contract Commercialization Organization will provide best-in-class teams with the required expertise in areas including and not limited to: Medical Affairs, Sales, Site Onboarding, Market Access and Regulatory Affairs.” There are currently 1369 cell and gene therapy developers worldwide generating over 2000 ongoing clinical trials. The majority of these trials are in Phase 2 and Phase 3. There is an expected bolus of novel agents to treat numerous niched disease populations. The expertise from specialized companies like CAR T Global Consultant Inc. will play a major role in ensuring these molecules reach the market in a timely and efficient manner. CAR T Global Consultant Inc. is proud to further elevate our mission of supporting cell & gene therapy organizations via this Full-Service Cell & Gene Therapy Specific Contract Commercialization Organization (CGT CCO) so that with flawless execution, they may bring their important assets to patients without delay.